Real-time intelligence on synbio and synbio funding, regulatory milestones, deployments, and policy.
Nature Biotechnology study demonstrates programmable diversity-generating retroelements for precise directed evolution
Read →New platform enables precise in vivo cancer gene screens with 4-fold reduced toxicity and temporal control
Read →Universal master cell banks slash production costs and patient attrition in NK cell therapies
Read →Japanese trust giant reduces Twist position by 19% as DNA synthesis sector faces headwinds
Read →Cellares demonstrates scalable autologous cell therapy production with first patient dosings
Read →Researchers demonstrate targeted silencing of extra chromosome 21 using CRISPR-based approach in Down syndrome cells
Read →Edinburgh fund manager boosts position in base editing pioneer amid sector consolidation
Read →Evercore maintains Buy rating for Editas Medicine with increased $15 target amid CRISPR program momentum
Read →New miniaturized CRISPR platform addresses AAV packaging limits that constrain therapeutic genome editing applications
Read →New NIH-backed research creates miniaturized CRISPR editors small enough for efficient viral delivery throughout the body
Read →Scientists develop CRISPR system that edits genes without cutting DNA, potentially solving off-target issues
Read →Goldman Sachs maintains Buy rating on Generate Biomedicines, lifting price target to $26 amid AI protein design momentum
Read →Five patients no longer need blood transfusions after Chinese CRISPR treatment, signaling cost-competitive challenge to US therapies
Read →CTX001 gene therapy achieves transfusion independence in 95% of patients with severe beta-thalassemia
Read →Cantor Fitzgerald initiates coverage of Generate Biomedicines with Buy rating, highlighting AI-driven protein design platform
Read →Swiss pharma giant expands decade-long C4 partnership to develop degrader-antibody conjugates targeting undruggable proteins
Read →Digital manufacturing advances drive plant-based protein production to competitive cost structure versus traditional platforms
Read →Sugar producer Magdalena launches massive precision fermentation facility, marking Central America's largest synbio investment
Read →David vs. Goliath patent victory reshapes CRISPR licensing landscape for next-gen gene editing platforms
Read →High-content CRISPR activation screens identify synthetic lethal RNA mechanisms to boost T cell cancer killing
Read →